Form 4: AnaptysBio Director Converts Restricted Stock Units into Common Shares

AnaptysBio, Inc. Director Rita Jain converted 7,330 Restricted Stock Units (RSUs) into common stock on June 15, 2025, as part of her compensation plan.

Summary

• Rita Jain, a Director of AnaptysBio, Inc. (ANAB), reported a transaction involving the conversion of Restricted Stock Units (RSUs) into common stock.
• On June 15, 2025, Ms. Jain acquired 7,330 shares of AnaptysBio Common Stock at a price of $0 per share through the exercise or conversion of derivative securities.
• This transaction resulted from the vesting of two tranches of RSUs: 1,300 RSUs from a grant vesting in three annual installments, and 6,030 RSUs from a grant vesting 100% on the date of the Issuer's 2025 annual meeting of shareholders.
• Following this transaction, Ms. Jain beneficially owns 11,864 shares of AnaptysBio Common Stock directly.
• Additionally, Ms. Jain retains 1,300 Restricted Stock Units, which are scheduled to vest on June 15, 2026.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (RSU conversion) which is neutral in sentiment. It reflects standard compensation practices and does not indicate any significant positive or negative operational or financial developments.

Future Outlook

The document details future vesting dates for remaining Restricted Stock Units, specifically June 15, 2026, for 1,300 units, indicating continued equity compensation for the reporting person.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies, particularly in the biotechnology sector where equity compensation is a standard practice for attracting and retaining talent.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock represents a standard form of equity compensation, which can lead to minor dilution over time but is generally expected as part of a company's compensation strategy.
• Employees: This transaction reflects the company's ongoing use of equity-based compensation, which is a common practice to align employee and director interests with shareholder value.

Next Steps

• The remaining 1,300 Restricted Stock Units held by Rita Jain are scheduled to vest on June 15, 2026, subject to continued service to the company.

Key Dates

Keywords

AnaptysBio, ANAB, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Compensation, Equity Compensation, Stock Ownership